CONTEXT: Glucokinase plays a key role in glucose homeostasis. Glucokinase activators can lower glucose levels in both animal and human type 2 diabetes, but their mechanism of action has never been explored in humans. OBJECTIVE: The objective of the study was to investigate the effects of the glucokinase activator piragliatin (RO4389620) on β-cell function and glucose fluxes in both fasting and fed (oral glucose tolerance test) states in patients with type 2 diabetes. DESIGN: This was a phase Ib randomized, double-blind, placebo-controlled crossover trial of two (25 and 100 mg) doses of piragliatin. SETTING: This study was conducted at a clinical research center. PATIENTS: Patients included 15 volunteer ambulatory patients with mild type 2 diabetes. INTERVENTIONS: Interventions included three 10-h (-300' to +300') studies, with an interval of at least 14 d. Administration of a single dose of placebo or piragliatin 25 mg or piragliatin 100 mg at -120'. Oral glucose tolerance test (at 0') with dual (iv and oral routes) tracer dilution technique was conducted. MAIN OUTCOME MEASURES: The primary measure was plasma glucose concentration. The secondary measure was model assessed β-cell function and tracer-determined glucose fluxes. RESULTS:Piragliatin caused a dose-dependent reduction of glucose levels in both fasting and fed states (P < 0.01). In the fasting state, piragliatin caused a dose-dependent increase in β-cell function, a fall in endogenous glucose output, and a rise in glucose use (all P < 0.01). In the fed state, the primary effects of piragliatin were on β-cell function (P < 0.01). CONCLUSIONS: The glucokinase activator piragliatin has an acute glucose-lowering action in patients with mild type 2 diabetes, mainly mediated through a generalized enhancement of β-cell function and through fasting restricted changes in glucose turnover.
RCT Entities:
CONTEXT: Glucokinase plays a key role in glucose homeostasis. Glucokinase activators can lower glucose levels in both animal and human type 2 diabetes, but their mechanism of action has never been explored in humans. OBJECTIVE: The objective of the study was to investigate the effects of the glucokinase activator piragliatin (RO4389620) on β-cell function and glucose fluxes in both fasting and fed (oral glucose tolerance test) states in patients with type 2 diabetes. DESIGN: This was a phase Ib randomized, double-blind, placebo-controlled crossover trial of two (25 and 100 mg) doses of piragliatin. SETTING: This study was conducted at a clinical research center. PATIENTS: Patients included 15 volunteer ambulatory patients with mild type 2 diabetes. INTERVENTIONS: Interventions included three 10-h (-300' to +300') studies, with an interval of at least 14 d. Administration of a single dose of placebo or piragliatin 25 mg or piragliatin 100 mg at -120'. Oral glucose tolerance test (at 0') with dual (iv and oral routes) tracer dilution technique was conducted. MAIN OUTCOME MEASURES: The primary measure was plasma glucose concentration. The secondary measure was model assessed β-cell function and tracer-determined glucose fluxes. RESULTS:Piragliatin caused a dose-dependent reduction of glucose levels in both fasting and fed states (P < 0.01). In the fasting state, piragliatin caused a dose-dependent increase in β-cell function, a fall in endogenous glucose output, and a rise in glucose use (all P < 0.01). In the fed state, the primary effects of piragliatin were on β-cell function (P < 0.01). CONCLUSIONS: The glucokinase activator piragliatin has an acute glucose-lowering action in patients with mild type 2 diabetes, mainly mediated through a generalized enhancement of β-cell function and through fasting restricted changes in glucose turnover.
Authors: Nicolai M Doliba; Wei Qin; Habiba Najafi; Chengyang Liu; Carol W Buettger; Johanna Sotiris; Heather W Collins; Changhong Li; Charles A Stanley; David F Wilson; Joseph Grimsby; Ramakanth Sarabu; Ali Naji; Franz M Matschinsky Journal: Am J Physiol Endocrinol Metab Date: 2011-09-27 Impact factor: 4.310
Authors: Bogumil Zelent; Stella Odili; Carol Buettger; Dorothy K Zelent; Pan Chen; Deborah Fenner; Joseph Bass; Charles Stanley; Monique Laberge; Jane M Vanderkooi; Ramakanth Sarabu; Joseph Grimsby; Franz M Matschinsky Journal: Biochem J Date: 2011-12-01 Impact factor: 3.857
Authors: J J Meier; T G K Breuer; R C Bonadonna; A Tannapfel; W Uhl; W E Schmidt; H Schrader; B A Menge Journal: Diabetologia Date: 2012-05 Impact factor: 10.122
Authors: Konstantinos A Toulis; Krishnarajah Nirantharakumar; Chrysa Pourzitaki; Anthony H Barnett; Abd A Tahrani Journal: Drugs Date: 2020-04 Impact factor: 9.546
Authors: Matthew C Surdel; Dennis J Horvath; Lisa J Lojek; Audra R Fullen; Jocelyn Simpson; Brendan F Dutter; Kenneth J Salleng; Jeremy B Ford; J Logan Jenkins; Raju Nagarajan; Pedro L Teixeira; Matthew Albertolle; Ivelin S Georgiev; E Duco Jansen; Gary A Sulikowski; D Borden Lacy; Harry A Dailey; Eric P Skaar Journal: Proc Natl Acad Sci U S A Date: 2017-07-24 Impact factor: 11.205
Authors: D J Baker; G P Wilkinson; A M Atkinson; H B Jones; M Coghlan; A D Charles; B Leighton Journal: Br J Pharmacol Date: 2014-04 Impact factor: 8.739